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Significance of anti.phospholipid antibodies in patients with lupus
nephritis. Anti-phospholipid antibodies (APA) as markers or mediators
of thrombosis in lupus could be of pathogenetic significance in nephri-
tis, since glomerular capillary thrombi are an indicator of subsequent
renal dysfunction. Isotype specific APA antibodies were measured,
using cardiolipin as the antigen, in 76 patients with lupus nephritis.
Twenty-nine percent of the patients had elevated IgG APA. Overall,
43% of patients showed raised levels of at least one isotype. In general,
APA had specificity for anionic phospholipids. In vitro lupus anticoag-
ulant activity was associated with all three isotypes of APA, but only
the 1gM isotype correlated with the biological false positive test for
syphilis. APA were not associated with thromboses or neurological
involvement, and only the IgA isotype correlated with thrombocytope-
nia. We confirmed an association between the presence of intra-
glomerular thrombi and serum IgG APA. However, we found no
association between APA and renal histological pattern, or long-term
renal function. Our data, therefore, do not support a major pathogenetic
role for APA in the nephritis of lupus in treated patients.
Nephritis is a major cause of death in patients with lupus, and
despite immunosuppression many evolve into renal failure [1].
There are a number of factors involved in this progression, but
there is growing evidence that it results in part from chronic
activation of coagulation systems [2, 3]. The importance of this
intravascular coagulation in lupus was demonstrated by Kant et
al [2], who first pointed out that the glomerular capillary
thrombi, well known to be associated with active lupus nephri-
tis [4], were in fact the best indicator of subsequent glomerulo-
sclerosis and decline in renal function. These findings have not,
however, been confirmed by another group [5].
Although there are many data on the relationship between
either lupus anticoagulant activity or anti-phospholipid antibod-
ies measured using ELISA systems in systemic lupus erythe-
matosus (SLE) as seen in Rheumatology clinics, there are few
data concerning the nephritis of SLE. Glueck et al [6] reported
a significant association between the presence of glomerular
capillary thrombi and functional lupus anticoagulant activity,
suggesting that antibodies directed against negatively-charged
phospholipids could have a pathogenic role through the devel-
opment of microthrombi [7]. More recently, Kincaid-Smith's
group have reported that the lupus anticoagulant was associated
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with renal thrombotic microangiopathy and pregnancy-related
renal failure in a series of 12 women, 4 of whom had systemic
lupus [8].
The introduction of solid-phase immunoassays [9] for anti-
anionic phospholipid antibodies, simpler and more sensitive
than the functional lupus anticoagulant tests, has made it
possible to study large numbers of patients for the presence of
these antibodies and make clinical and other associations.
Therefore, using ELISA systems immunoglobulins G (IgG), M
(1gM), or A (IgA) with specificity for the phospholipid cardio-
lipin were measured in the sera of 76 patients with lupus
nephritis, and in 100 normal controls. Second, the specificity of
the APA was evaluated by seeing which phospholipid or DNA
could inhibit its binding. Third, serological correlations were
sought between APA and the lupus anticoagulant (LAC), and
the biologically false positive test for syphilis (BFPTS). Finally,
clinicopathologic associations were also determined between
APA and thromboses, thrombocytopenia, neurological involve-
ment, renal histology, presence of intra-glomerular capillary
thrombi, and renal function.
Methods
Patients
All 76 patients studied satisfied the criteria of the American
Rheumatism Association (ARA) [10] for the diagnosis of SLE,
and all had clinically evident nephritis. Sixty-five patients were
taking prednisolone, and 50 azathioprine as well at the time of
study. All patients had a renal biopsy performed. APA were
also measured in the sera of 100 normal blood donors.
Frequency of APA in normal and lupus nephritis patients
IgG, 1gM and IgA anti-phospholipid (cardiolipin) antibody
ELISA. Anti-phospholipid antibodies were measured using a
modified solid-phase enzyme linked immunoassay [11] on poly-
vinylchloride, "high activated" microtiter plates (Flow Labo-
ratories, Irvine, Scotland, UK) coated with 10 d of a 1 mg/mI
cardiolipin solution in ethanol (Sigma Chemicals Co., St Louis,
Missouri, USA). The ethanol was rapidly evaporated in a 37°C
incubator for 15 minutes to leave a final cardiolipin concentra-
tion of 10 g per well. The wells were washed three times for
three minutes in a 0.15 M phosphate buffered saline (PBS), pH
7.4 and 1 mM ethylenediaminetetra-acetic acid (EDTA) and
0.3% wt/vol gelatin (BDH, Poole, Dorset, UK). One hundred
microliters of 2% bovine serum albumin (BSA) (Sigma Chemi-
cal Co.), PBS-gelatin EDTA was added to each well and
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incubated for one hour at room temperature to reduce non-
specific binding of immunoglobulins to the well surface. After
three washes in PBS-gelatin EDTA, 50 d duplicate samples of
test serum, known positive SLE serum or normal control,
diluted (1:100 for IgG and 1gM or 1:10 for IgA) in 2% BSA,
PBS-gelatin EDTA, were added to each well, and incubated for
90 minutes at room temperature. After three washes, 50 l of
affinity-purified goat anti-human IgG, 1gM, or IgA alkaline
phosphatase conjugate (Tago, Burlingame, California, USA)
diluted 1:1000 in 2% BSA, PBS-gelatin EDTA was added to
each well for a further 90 minutes incubation at room temper-
ature. After a further three washes, 100 d of p-nitrophenyl
phosphate (Sigma Chemical Co.) at a concentration of 1 mg/mI
in 10% vol/vol diethanolamine buffer (pH 9.8) was added to
each well and incubated for one hour at room temperature. The
reaction was stopped by adding 50 d of 3 M NaOH per well,
and the optical density (OD) at 410 nm read in a Dynatech
ELISA spectrophotometer. Antibody levels were expressed as
a percentage of the amount of APA (OD) found in the internal
reference serum (IRS), from patient with active SLE, known to
contain high levels for all three isotypes. A standard curve was
also used in each assay. Test samples with OD readings similar
to, or above the IRS were further diluted, and re-assayed to
obtain a value on the linear part of the standard curve. A normal
range for each antibody class was established from the sera of
100 blood donors.
Specificity of APA
Inhibition experiments were designed to examine the cross
reactivity of: a) anti-phospholipid antibodies and b) anti-DNA
antibodies.
Patients. Sera from 15 of 76 patients with lupus nephritis with
elevated IgG APA were studied. Five of 76 patients with high
IgG antibodies to double-stranded deoxyribonucleic acid (ds-
DNA) or single-stranded DNA (ssDNA) were also studied.
DNA-binding antibody ELISA was performed as described
previously [121.
Phospholipids. Cardiolipin (CL) in ethanol; phosphatidyleth-
anolamine (PE), phosphatidyicholine (PC), and phosphatidyl-
inositol (P1) in chloroform; phosphatidylglycerol (PG) and phos-
phatidylserine (PS) in chloroform/methanol; and phosphatidic
acid (PA) and sphingomyelin (SM) were purchased from Sigma
Chemicals. Phosphatidic acid and sphingomyelin were dis-
solved in methanollchloroform (2:1) prior to use.
The organic solvents in which the phospholipids were dis-
solved were evaporated to dryness under nitrogen. The phos-
pholipids were then resuspended in 0.15 M sodium chloride and
0.15 M sodium citrate pH 7 by sonication (MSE, Crawley,
Sussex, UK) at maximum intensity for 15 seconds. All the
phospholipids were used at 1 mg/mI and where necessary,
differing concentrations of the phospholipid suspensions were
prepared by dilution in PBS with continuous vortex mixing.
DNA. One milligram of dsDNA (calf thymus, Sigma Chemi-
cals) was dissolved in 1 ml of PBS for use in the inhibition
studies. ssDNA was prepared from the 1 mg/mI dsDNA by
heating at 100°C for 10 minutes, then immersing the solution in
ice. Both ds and ssDNA were used at I mg/ml.
Inhibition studies. The patient's serum samples were diluted,
in 2% BSA/0.3% gelatinlPBS for the APA assays or 1% BSA/
TweenIPBS for the anti-DNA assays, to give optical density
(OD) readings of 1.0 in the different ELISA systems. One
hundred and eighty microliter aliquots of the diluted samples
were mixed with 20 .d aliquots of the phospholipid or DNA
suspensions (or PBS as the uninhibited control) to give final
inhibitor concentrations of 100 jLg/ml. The mixtures were then
incubated at 37°C for one hour and 4°C overnight with constant
mixing.
The results of the inhibition studies were calculated as
described by Harris et a! [13].
APA and serological correlations
APA and lupus anticoagulant. The "lupus anticoagulant"
test was performed on the plasma of 32 of the 76 patients using
the activated partial thromboplastin time assay (APTT) as
described by Procter and Rapaport [14]. In brief, this examines
the prolongation of a phospholipid-dependent coagulation in
vitro, and the ability of normal plasma to inhibit this when
mixed in 1:1 proportions. In the presence of "lupus anticoagu-
lant" this prolongation is not inhibited.
APA and biologically false positive test for syphilis. This test
was performed on the sera of 34 of our 76 patients with lupus
nephritis using the commercially available Oxoid Rapid Reagin
Card Test (Oxoid Ltd, Basingstoke, UK) and following the
manufacturer's instructions.
APA and clinicopathologic associations
A) Extra-renal. Clinical information was available on all 76
patients to study the associations of extra-renal complications
with APA concentrations. These clinical events included
thromboses, thrombocytopenia, and neurological involvement.
(i) Thromboses. Eight patients suffered thrombotic events,
which were as follows: axillary vein thrombosis (N = 1),
multiple pulmonary emboli (N = 2), thrombotic thrombocy-
topenic purpura (N = 1), renal vein thrombosis (N 2),
thrombosis of right atrium (N = 1), and coronary ischemic
attack (N 1).
(ii) Thrombocytopenia. Ten patients had platelet counts of
less than 150,000 jLl, of which 5 had platelet counts of less than
100,000 jd. In this study all 10 patients were defined as
thrombocytopenic.
(iii) Neurological involvement. Twenty patients had some
form of neurological involvement, and were as follows: mi-
graine (N = 5), mononeuritis (N = 1), psycotic illness (N 4),
stroke (N 1), depressive psychosis (N 4), anxiety neurosis
(N = 1), transient ischemic attacks (N = 1), hemiparesis (N =
1), retinal vasculitis (N 1), and brain abscess (N = 1).
B) Renal. (i) APA and renal histology: Morphology and
intraglomerular thrombi. Hematoxylin and eosin stain (H and
E) were performed as follows: paraffin-embedded kidney sec-
tions of 37 biopsies from 33 of 76 lupus patients, in whom a
contemporary serum for APA estimations, were stained in
Meyers Haematoxylin (Raymond A. Lamb, Wembley, Middle-
sex, UK) for five minutes and then counterstained in 1% Eosin
(Raymond A. Lamb) for two minutes and washed in tap water.
The morphology of these renal biopsies was classified by an
experienced renal histopathologist (Dr. B.M. Hartley). The
renal morphological findings were divided into two groups: (1)
Severe nephritis, those with severe focal proliferative nephritis
(WHO class Ilib), and those with diffuse proliferative glomer-
ulonephritis (WHO class IV) (including mesangiocapillary gb-
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Fig. 1. IgG, 1gM, and IgA anti-phospholipid
(cardiolipin) antibody (APA) concentrations in 100
normal blood donors. The antibody distributions in
____________ the normal controls were asymmetrical. Any points
lying outside the normal distribution were regarded
as abnormal. Antibody levels were expressed as the
percentage of APA optical density found in the
internal standard serum.
merulonephritis) with or without crescents (N = 23). (2) Less
severe, those with membranous (WHO class V) and less severe
focal proliferative glomerulonephritis [WHO class 111(a) or
mesangial lesions only (WHO class II)] (N = 14). No patient
had WHO class I appearances (minimal changes).
The presence of platelets was confirmed in kidney sections
showing hyaline "thrombi" by the peroxidase anti-peroxidase
method employing rabbit anti-thrombocyte antiserum (Dako
Ltd, High Wycombe, Bucks, UK). The fixed platelet antigens
were unmasked with 1 mg/mI pronase (Sigma).
(ii) APA and renal function. The plasma creatinine concen-
tration was employed as an index of kidney function measured
by a rate dependent Jaffé reaction in a Hitachi 737 analyzer, and
levels less than 130 mol/liter were considered normal. Renal
function at the time of kidney biopsy was compared with that at
the end of the follow-up period (8 to 89 months). Long-term
follow-up information was avalable on 59 of 76 of the patients.
Patients were divided into four groups: 1) those with normal
renal function at the time of biopsy, and at the end of the
follow-up period, 2) patients with reduced renal function at the
time of biopsy, but with normal function at the end of the
follow-up period, 3) patients with normal function at biopsy but
reduced function at the end of the follow-up study, and 4) those
with reduced renal function at the time of biopsy, which
worsened during the follow-up period. For statistical analysis
the four groups were amalgamated into two main groups: 1 and
2 = good renal function; 3 and 4 = bad renal function.
Statistics
Statistical associations were sought using Fishers exact prob-
ability test.
Results
Frequency of APA in normal and lupus nephritis patients
APA ELISA: Intra- and intercoefficients of variation, The
intra-plate coefficients of variations for IgG, 1gM, and IgA APA
ELISA's were 5%, 3%, and 5%, respectively. The inter-plate
coefficints of variation for the IgG, 1gM and IgA APA ELISA's
were 8%, 7%, and 8%, respectively.
Normals. The distribution of anti-phospholipid antibodies in
the normal controls (N = 100) was asymmetrical and the events
discontinuous so that parametric statistics could not be em-
ployed. The 95 percentile of APA values for normal controls
was used to establish the normal range for each isotype (Fig. 1)
Values of IgG APA > 25%, 1gM APA> 16% and IgA APA>
21% were regarded as elevated.
Patients: IgG APA. Twenty-nine percent (22 out of 76) of the
patients with lupus nephritis had high levels of IgG APA
compared with 3% (3 out of 100) of normal controls (Fig. 2A).
1gM APA. 1gM APA levels were elevated in 16% (12 out of
76) of patients with lupus nephritis compared with 4% (4 out of
100 ) of the normal blood donors.
IgA APA. The IgAAPA were raised above the normal range
in 19 (25%) of the 76 patients with lupus nephritis compared
with 5 (5%) of the 100 normal controls.
The distribution of the three isotypes in the APA positive
patients is represented as a Venn diagram in Figure 2B. In all,
33 patients out of 76 (43%) showed raised levels of at least one
isotype of APA.
Spec(ficity of APA
Inhibition studies: (a) Cross reactivity of anti-phospholipid
antibodies. Fifteen sera with elevated IgG APA from our 76
patients with lupus nephritis were examined in the IgG APA
ELISA for inhibition by various phospholipids, and by ss- or
ds-DNA. The results for these inhibition experiments are listed
on Table 1. In general, the anionic phospholipids phosphatidic
acid (PA), phosphatidyl inositol (P1), phosphatidyl serine (PS),
phoshatidyl glycerol (PU), cardiolipin (CL) gave similar, high
levels of inhibition in the IgG, 1gM and IgA APA ELISA.
Interestingly, IgG APA from the serum of patient 3 in the IgG
APA ELISA showed no inhibition with the anionic phospho-
lipids PA, P1, and PS, but PG (and CL) did inhibit the binding.
With the exception of sphingomyelin, the zwitterionic phos-
pholipids gave little inhibition of the APA in the sera tested. The
level of inhibition by sphingomyelin was, however, much less
than that obtained by the negatively-charged phospholipids.
Similarly, neither ss- or ds-DNA inhibited APA, except in
patients 14 and 15. These levels of inhibition were considered
significant, because they were greater than the inter-plate
coefficient of variation (8%) for the IgG APA ELISA.
(b) Inhibition of anti-ss or -dsDNA antibody with cardiolipin.
Sera with high IgG anti-ssDNA and anti-dsDNA from five
patients with lupus nephritis were tested for inhibition by
cardiolipin. The degree of inhibition by cardiolipin was very
small and did not rise above the inter-plate coefficients of
variation (12%) for the specific ELISAs employed. This level of
inhibition was therefore not considered significant (data not
shown).
APA and serological correlations
APA and "lupus anticoagulant" activity. Comparison of IgG
APA titers and the activated partial thromboplastin times
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Fig. 2. A. Elevated IgG, 1gM and IgA anti-phospholipid (cardiolipin)
antibody (APA) levels in 76 patients with lupus nephritis. Numbers in
the shaded boxes, which represent the the upper limit of 95 of the 100
normal serum samples, are within the normal range (Fig. 1). Antibody
levels were expressed as a percentage of APA optical density found in
the internal standard serum. B. Venn diagram representation of ele-
vated APA isotypes within a population of 76 patients with lupus
nephritis. Forty-three percent (33) of patients had raised levels of at
least one isotype.
(APTT) in the plasma of 32 of the patients with lupus nephritis
is shown in Figure 3. The IgG APA isotype was highly signifi-
cantly associated with the APTT (P = 0.0001), with only 3 of 15
patients positive for lgG APA being negative for APTT (less
than 44 sec) and 2 of 14 patients with abnormal APTT had
normal IgG APA (less than 25%). Therefore, 80% of the 32
lupus nephritis patients with IgG APA also had the lupus
anticoagulant.
In contrast, the 1gM and IgA isotypes were weakly associated
with the APTT (P = 0.02 and P = 0.03, respectively). The
proportion of patients positive for both 1gM APA and the lupus
anticoagulant was similar to that of the IgA APA isotype; 62%
as compared with 64%, respectively (data not shown).
APA and biologically flilse-positive test for syphilis. Class-
specific APA and VDRL titers were measured in 34 lupus
nephritis patients, using the same serum sample for both
determinations. 1gM APA, but not IgG or IgA isotypes corre-
lated with the VDRL titers (P = 0.007). Fifty percent of the
patients with raised 1gM APA were also VDRL positive,
Percent inhibition of IgG anti-cardiolipin antibody in the sera of 15
patients with lupus nephritis by phospholipids including: phosphatidic
acid (PA), phosphatidyl inositol (P1), phosphatidyl serine (PS), phos-
phatidyl glycerol (PG), cardiolipin (CL), phosphatidyl choline (PC),
phosphatidyl ethanolamine (PE), sphingomyelin (SM), and by single
(ss) or double-stranded (ds) DNA.
compared with 33% for IgG and 29% for IgA isotype (data not
shown).
APA and clinicopathologic associations
(A) Extra-renal: (i) Thromboses. No statistical associations
were found between the presence of thrombotic events in 8 of
76 patients and APA levels (data not shown).
(ii) Thrombocytopenia. IgA APA, but not IgG or 1gM, were
associated with low platelet counts (P = 0.007) in 10 of 76
patients with lupus nephritis.
(iii) Neurological involvement. No statistical associations
were found between the levels of APA and neurological in-
volvement in 20 of 76 patients with lupus nephritis.
(B) Renal: (i) APA and renal morphology. Associations were
sought between serum IgG APA, 1gM APA and IgA APA taken
at the time of the biopsy (± 2 weeks) and the 'bad prognosis'
renal morphology.
No statistically significant associations were found.
(ii) APA and intragiomerular thrombi. The number of "hya-
line" thrombi (Fig. 4) per number of glomeruli were also
recorded by the histopathologist. We studied a total of 1072
glomeruli in the 37 renal biopsies for the presence of any
"hyaline" thrombi. For statistical analysis, biopsies containing
more than one intraglomerular capillary thrombus were graded
as positive (N 14) and those with one or no thrombi were
called negative (N = 23).
Again, correlations were sought between the presence of two
or more hyaline thrombi and abnormal APA levels. Seven of 14
biopsies with two or more thrombi had high levels of IgG APA
compared with 3 of 23 biopsies with one or less thrombi (P=
0.0 19).
In contrast, no correlations were found between the presence
of two or more thrombi and 1gM APA, IgA APA or IgG
anti.dsDNA antibody.
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Fig. 3. Statistical association between the
activated partial thromboplastin time (APTT)
and IgG anti-phospholipid (cardiolipin)
antibody (APA) in 32 of the 76 patients with
lupus nephritis (P = 0.0001, Fishers exact
probability test).
(iii) APA and renal function. Renal function was assessed by
examining serum creatinine concentrations at the time of renal
biopsy and at the end of the follow-up period (8 to 89 months).
Normal or improving renal function (N = 52). Forty-five
patients had normal renal function (serum creatinine < 130
molIliter) at the time of the renal biopsy, and at the end of the
follow-up period. Seven patients had reduced renal function at
the time of renal biopsy, but had normal renal function at the
end of the follow-up period.
Worsening renal function (N = 7). Four patients had normal
renal function at the time of the biopsy but had reduced function
at the end of the follow-up period. Lastly, three patients had
reduced renal function at the time of biopsy, which deteriorated
further during the time of the follow-up period.
No statistical associations were found between those patients
with worsening renal function and APA.
Discussion
Many groups have reported that circulating anti-phospholipid
antibodies are statistically associated with increased incidence
of thrombosis, recurrent fetal loss, thrombocytopenia, and
neurological involvement [15], but little is actually known
whether these autoantibodies directly cause thrombosis, or by
what mechanism. Furthermore, several recent reports [16, 17]
have demonstrated that these antibodies may not even be
directed against the phospholipid itself, but against a 50 kD
cofactor which in some way binds to phospholipids, perhaps
after complexing with antibody.
Nevertheless, measurement of antibodies which appear to
bind to phospholipid in an ELISA system may be clinically
useful. These antibodies may in part be responsible for glomer-
ular capillary thrombi, which are often seen in active lupus
nephritis [4], and may therefore cause chronic activation of the
coagulation system within the kidney which is an important
factor in the development of glomerulonephritis and decline of
renal function [2, 3]. Little information has been published,
however, on the clinical significance of anti-phospholipid (car-
diolipin) antibody (APA) in the nephritis of lupus.
Frequency of APA in lupus nephritis
The IgG and 1gM APA ELISA systems described in this
study were validated at an international workshop [18]. IgA
APA ELISAs, however, were not included in the workshop and
data from this assay, therefore, have to be interpreted with
caution. We found that 29% of 76 patients with lupus nephritis
had high levels of IgG APA. Petri et al [19] reported a similar
incidence of 25% positive IgG APA in a series of 60 SLE
patients, which included 43 with lupus nephritis.
Specificity of APA
In the present study, APA were inhibited predominantly by
anionic, but not by zwitterionic phospholipids or DNA, as in
the data of Harris et al [13]. Conversely, anti-DNA antibodies
were not inhibited by cardiolipin, and therefore although some
murine monoclonal anti-ssDNA antibodies have been shown to
cross react with cardiolipin [201 perhaps due to the sharing of
similar phosphodiester moieties, this seems not to be the case
with human polyclonal anti-DNA antibodies [13, 21].
Immunological correlations of APA
Thirty-two of our 76 patients were also tested for "lupus
anticoagulant" activity. Eighty percent of 32 patients with
lupus nephritis with elevated IgG APA also had "lupus antico-
agulant" activity present in plasma. This finding is similar to
that described by Lockshin et al [22] in a series of 50 pregnant
patients with SLE (renal status not defined), who observed that
76% of their patients had APA as well as the "lupus anticoag-
ulant". We found larger discrepancies between the 1gM and
IgA APA isotypes compared with the IgG APA isotype and the
presence of the "lupus anticoagulant"; approximately 37% of
the 36 patients with either 1gM or IgA APA showing no
evidence of its presence. APA ELISA and the "lupus antico-
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with lupus nephritis, perhaps because the number of such
events (N = 8) was small. In a further study (Frampton et a!,
manuscript in preparation) we have shown an association
between APA and thromboses in patients with "lupus-like"
anti-nuclear factor negative nephritis [261. Some of these pa-
tients may have the so-called "antiphospholipid syndrome" as
described by Hughes, Asherson and Khamashta [271. However,
patients with "lupus-like" disease had high APA levels, but in
general no, or only mild nephritis.
Inverse relationships between APA and thrombocytopenia
have been reported previously [7, 9, 28] in lupus as a whole. We
have confirmed this observation in our patients with nephritis,
but only for the IgA isotype. These data suggest that some APA
may bind to platelets and lead to platelet removal, and we [29]
have shown increased APA on platelet membranes in patients
with lupus nephritis.
We found no association between APA and neurological
involvement in the patients studied. Our findings are therefore
in agreement with Weidmann et al [30] who measured APA
(including the IgA isotype) in 92 patients with SLE, including 9
with neurological involvement.
APA and the kidney
Fig. 4. Kidney sections from a patient with diffuse proliferative lupus
nephritis. Top section was stained with hemotoxylin and eosin (x400)
and the bottom section was stained with immunoperoxidase using
anti-platelet antibody (x 1000 magnification). Arrows indicate the gb-
merular capillary thrombi.
agulant" test may be measuring similar anti-phospholipid anti-
body populations in some, but not necessarily all patients.
VDRL results were available on 34 of 76 patients with lupus
nephritis. Eighteen percent of the 34 patients with lupus nephri-
tis had low titer positive VDRL tests. A false positive VDRL
has been reported in 10 to 30% of patients with SLE [231, and
constitutes one of the 11 ARA criteria for the diagnosis of SLE
[10]. Some workers have reported associations between APA
and false-positive VDRL [9, 24], while others have not [13, 251.
In the present study, only 1gM APA correlated with the BFPTS:
50% of 12 patients with elevated 1gM APA also had positive
VDRL titers. About one third of our lupus patients had either
IgG or IgA APA and a BFPTS. 1gM antibodies, because of their
multivalent structure, are good agglutinators and the VDRL test
is, of course, an agglutination test. This could explain the
observation of 1gM APA, but not IgG or IgA APA, correlating
with BFPTS.
APA and extra-renal clinical associations
In contrast to other workers [9, 19] we found no statistical
association between APA and thrombotic events in patients
In agreement with Valencia et a! [31], we found no relation-
ship between renal morphology defined by WHO classification
in 37 biopsies from 33 of our 76 SLE patients and the presence
of simultaneously determined levels of APA. However, unlike
Valencia et al [31], we did find an association between the
presence of intraglomerular capillary thrombi and IgG APA (but
not 1gM or IgA isotypes). Our data are therefore in agreement
with Glueck et al [61, who reported an association between the
presence of glomerular capillary thrombi and the functional
lupus anticoagulant. Therefore, antibodies directed against neg-
atively-charged phospholipids could have a pathogenetic role in
some patients through the release of platelet-derived inflamma-
tory proteins [3] from APA-induced microthrombi.
However, we found no association between renal function as
estimated by plasma creatinine, and APA were found in the 59
of 76 of our SLE patients in whom long-term follow-up data
were available. This could be a result of the small numbers of
patients with worsening renal function studied (N = 7), or
perhaps the follow-up period was too short (8 to 89 months) in
what is now, under immunosuppressive treatment, an indolent
disease (McLigeyo et al, manuscript submitted for publication)
in which renal failure is relatively uncommon. The lack of
association could also be a direct result of this treatment.
In summary, we showed no association between APA and
renal histological pattern, or long-term renal function, and
therefore our data do not support a major pathogenetic role for
these antibodies in the nephritis of immunosuppressed patients.
However, we did find an association between IgG APA and
glomerular capillary thrombi, which are often seen in active
disease [4]. It is interesting to speculate that APA-mediated
glomerular thrombi, and hence release of platelet-derived in-
flammatory proteins may contribute, in some patients, to the
genesis of nephritis. Further work is required, however, to
prospectively study the relationship between anti-phospholipid
antibodies, glomerular capillary thrombi, and long-term renal
function in patients with systemic lupus to determine whether
these antibodies contribute to the pathology of the kidney.
I 
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